News
Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates.
4d
Stocktwits on MSNWegovy for $299? Retail Buzz Erupts As WeightWatchers, Novo Nordisk Expand Obesity Drug PushRetail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.
Review the current Novo Nordisk AS ADR (NVO:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NVO is the best investment for you.
See the latest Novo Nordisk AS Class B stock price (NOVO B:XCSE), related news, valuation, dividends and more to help you make your investing decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results